{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:27:20Z","timestamp":1788582440203,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Anesthesiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pharmacogenetics could represent a further resource to understand the interindividual heterogeneity of response of the host to sepsis and to provide a personalized approach to the critical care patient.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Secondary analysis of data from the prospective observational study NCT02750163, in 50 adult septic and septic shock patients treated with Acetaminophen (ACT) for pyrexia. We investigated the presence of two polymorphisms, located respectively in the genes <jats:italic>UGT1A1<\/jats:italic> and <jats:italic>CYP3A5,<\/jats:italic> that encode for proteins related to the hepatic metabolism of ACT. The main dependent variables explored were plasmatic concentration of ACT, body temperature and hepatic parameters.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>8% of the patients carried <jats:italic>CYP3A5<\/jats:italic> rs776746 A\/G genotypes and showed significantly higher plasma levels of ACT than\u00a0GG wild type patients, and\u00a0than patients with <jats:italic>UGT1A1<\/jats:italic> rs8330 C\/G genotypes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Identifying specific genotypes of response to ACT may be helpful to guide a more personalized titration of therapy in sepsis and septic shock. <jats:italic>CYP3A5<\/jats:italic> might be a good biomarker for ACT metabolism; however further studies are needed to confirm this result.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>NCT02750163.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12871-023-02018-y","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T06:29:07Z","timestamp":1676528947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacogenetics in critical care: association between CYP3A5 rs776746 A\/G genotype and acetaminophen response in sepsis and septic shock"],"prefix":"10.1186","volume":"23","author":[{"given":"C.","family":"Scorcella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Domizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Amoroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Carsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Casarotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Castaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"D\u2019angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gasparri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Adrario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"issue":"3","key":"2018_CR1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2478\/jccm-2019-0017","volume":"5","author":"A Laz\u0103r","year":"2019","unstructured":"Laz\u0103r A, Georgescu AM, Vitin A, Azamfirei L. Precision Medicine and its Role in the Treatment of Sepsis: A Personalised View. J Crit Care Med (Targu Mures). 2019;5(3):90\u20136. https:\/\/doi.org\/10.2478\/jccm-2019-0017. PMID:31431921;PMCID:PMC6698074.","journal-title":"J Crit Care Med (Targu Mures)"},{"issue":"12","key":"2018_CR2","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.cmi.2018.03.011","volume":"24","author":"J Rello","year":"2018","unstructured":"Rello J, van Engelen TSR, Alp E, Calandra T, Cattoir V, Kern WV, Netea MG, Nseir S, Opal SM, van de Veerdonk FL, Wilcox MH, Wiersinga WJ. Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect. 2018;24(12):1264\u201372. https:\/\/doi.org\/10.1016\/j.cmi.2018.03.011. Epub 2018 Mar 24 PMID: 29581049.","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"2018_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/1744666X.2019.1562336","volume":"15","author":"N Bruse","year":"2019","unstructured":"Bruse N, Leijte GP, Pickkers P, Kox M. New frontiers in precision medicine for sepsis-induced immunoparalysis. Expert Rev Clin Immunol. 2019;15(3):251\u201363. https:\/\/doi.org\/10.1080\/1744666X.2019.1562336. Epub 2019 Jan 7 PMID: 30572728.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"2018_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4037\/aacnacc2018398","volume":"29","author":"D Cheek","year":"2018","unstructured":"Cheek D, Howington L. Pharmacogenomics in Critical Care. AACN Adv Crit Care. 2018;29(1):36\u201342. https:\/\/doi.org\/10.4037\/aacnacc2018398. PMID: 29496712.","journal-title":"AACN Adv Crit Care."},{"key":"2018_CR5","doi-asserted-by":"publisher","unstructured":"Luzum JA, Petry N, Taylor AK, Van Driest SL, Dunnenberger HM, Cavallari LH. Moving Pharmacogenetics Into Practice: It\u2019s All About the Evidence! Clin Pharmacol Ther. 2021;110(3):649\u201361. https:\/\/doi.org\/10.1002\/cpt.2327. Epub 2021 Jul 7. PMID: 34101169; PMCID: PMC8376790.","DOI":"10.1002\/cpt.2327"},{"issue":"9","key":"2018_CR6","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.3389\/fphar.2018.01436","volume":"4","author":"S Zhou","year":"2018","unstructured":"Zhou S, Skaar DJ, Jacobson PA, Huang RS. Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit. Front Pharmacol. 2018;4(9):1436. https:\/\/doi.org\/10.3389\/fphar.2018.01436. PMID:30564130;PMCID:PMC6289166.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2018_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2174\/1389200215666140130124910","volume":"15","author":"KE Caudle","year":"2014","unstructured":"Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab. 2014;15(2):209\u201317. https:\/\/doi.org\/10.2174\/1389200215666140130124910.","journal-title":"Curr Drug Metab"},{"issue":"5","key":"2018_CR8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2174\/138920011795495277","volume":"12","author":"M Stojiljkovic","year":"2011","unstructured":"Stojiljkovic M, Patrinos GP, Pavlovic S. Clinical applicability of sequence variations in genes related to drug metabolism. Curr Drug Metab. 2011;12(5):445\u201354. https:\/\/doi.org\/10.2174\/138920011795495277. PMID: 21453274.","journal-title":"Curr Drug Metab"},{"issue":"1","key":"2018_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1124\/dmd.113.053546","volume":"42","author":"MH Court","year":"2014","unstructured":"Court MH, Peter I, Hazarika S, Vasiadi M, Greenblatt DJ, Lee WM, Acute Liver Failure Study Group. Candidate gene polymorphisms in patients with acetaminophen-induced acute liver failure. Drug Metab Dispos. 2014;42(1):28\u201332. https:\/\/doi.org\/10.1124\/dmd.113.053546. Epub 2013 Oct 8. PMID: 24104197; PMCID: PMC3876784.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"2018_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1124\/jpet.112.202010","volume":"345","author":"MH Court","year":"2013","unstructured":"Court MH, Freytsis M, Wang X, Peter I, Guillemette C, Hazarika S, Duan SX, Greenblatt DJ, Lee WM, Acute Liver Failure Study Group. The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a\/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure. J Pharmacol Exp Ther. 2013;345(2):297\u2013307. https:\/\/doi.org\/10.1124\/jpet.112.202010. Epub 2013 Feb 13. PMID: 23408116; PMCID: PMC3629801.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2018_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/00498250802512830","volume":"39","author":"JE Laine","year":"2009","unstructured":"Laine JE, Auriola S, Pasanen M, Juvonen RO. Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica. 2009;39(1):11\u201321. https:\/\/doi.org\/10.1080\/00498250802512830. PMID: 19219744.","journal-title":"Xenobiotica"},{"issue":"9","key":"2018_CR12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","volume":"11","author":"E Hustert","year":"2001","unstructured":"Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockm\u00f6ller J, Halpert JR, Zanger UM, Wojnowski L. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001;11(9):773\u20139. https:\/\/doi.org\/10.1097\/00008571-200112000-00005. PMID: 11740341.","journal-title":"Pharmacogenetics"},{"issue":"5","key":"2018_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fgene.2014.00314.PMID:25352860;PMCID:PMC4196544","volume":"14","author":"AE Krasniak","year":"2014","unstructured":"Krasniak AE, Knipp GT, Svensson CK, Liu W. Pharmacogenomics of acetaminophen in pediatric populations: a moving target. Front Genet. 2014;14(5):314. https:\/\/doi.org\/10.3389\/fgene.2014.00314.PMID:25352860;PMCID:PMC4196544.","journal-title":"Front Genet"},{"issue":"3","key":"2018_CR14","doi-asserted-by":"publisher","first-page":"155932581772373","DOI":"10.1177\/1559325817723731","volume":"15","author":"H Mehboob","year":"2017","unstructured":"Mehboob H, Tahir IM, Iqbal T, Saleem S, Perveen S, Farooqi A. Effect of UDP-Glucuronosyltransferase (UGT) 1A Polymorphism (rs8330 and rs10929303) on Glucuronidation Status of Acetaminophen. Dose-Response. 2017;15(3):1559325817723731. https:\/\/doi.org\/10.1177\/1559325817723731.","journal-title":"Dose-Response"},{"issue":"1","key":"2018_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12630-016-0748-1","volume":"64","author":"M MacKenzie","year":"2017","unstructured":"MacKenzie M, Hall R. Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review. Can J Anaesth. 2017;64(1):45\u201364. https:\/\/doi.org\/10.1007\/s12630-016-0748-1. Epub 2016 Oct 17. PMID: 27752976.","journal-title":"Can J Anaesth"},{"issue":"1","key":"2018_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrd1285","volume":"3","author":"BD Freeman","year":"2004","unstructured":"Freeman BD, McLeod HL. Challenges of implementing pharmacogenetics in the critical care environment. Nat Rev Drug Discov. 2004;3(1):88\u201393. https:\/\/doi.org\/10.1038\/nrd1285. PMID: 14708023.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"2018_CR17","doi-asserted-by":"publisher","first-page":"738","DOI":"10.2174\/138920008786049302","volume":"9","author":"SF Zhou","year":"2008","unstructured":"Zhou SF, Di YM, Chan E, Du YM, Chow VD, Xue CC, Lai X, Wang JC, Li CG, Tian M, Duan W. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab. 2008;9(8):738\u201384. https:\/\/doi.org\/10.2174\/138920008786049302. PMID: 18855611.","journal-title":"Curr Drug Metab"},{"issue":"2","key":"2018_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1046\/j.13652125.2002.01630.x","volume":"54","author":"K Lindpaintner","year":"2002","unstructured":"Lindpaintner K. Pharmacogenetics and the future of medical practice. Br J Clin Pharmacol. 2002;54(2):221\u201330. https:\/\/doi.org\/10.1046\/j.13652125.2002.01630.x. PMID:12207645;PMCID:PMC1874402.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2018_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2174\/1389200215666140130124910","volume":"15","author":"KE Caudle","year":"2014","unstructured":"Caudle KE, Klein TE, Hoffman JM, Muller DJ, Whirl-Carrillo M, Gong L, McDonagh EM, Sangkuhl K, Thorn CF, Schwab M, Agundez JA, Freimuth RR, Huser V, Lee MT, Iwuchukwu OF, Crews KR, Scott SA, Wadelius M, Swen JJ, Tyndale RF, Stein CM, Roden D, Relling MV, Williams MS, Johnson SG. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab. 2014;15(2):209\u201317. https:\/\/doi.org\/10.2174\/1389200215666140130124910. PMID:24479687;PMCID:PMC3977533.","journal-title":"Curr Drug Metab"},{"key":"2018_CR20","doi-asserted-by":"publisher","unstructured":"H. Court M, Freytsis M, Wang X, Peter I, Guillemette C, Hazarika S, Duan SX, Greenblatt DJ, Lee WM and the Acute Liver Failure Study Group. The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a\/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure. J Pharmacol Exp Ther.\u00a02013;345(2):297\u2013307.\u00a0https:\/\/doi.org\/10.1124\/jpet.112.202010","DOI":"10.1124\/jpet.112.202010"}],"container-title":["BMC Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-023-02018-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12871-023-02018-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-023-02018-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T06:29:17Z","timestamp":1676528957000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcanesthesiol.biomedcentral.com\/articles\/10.1186\/s12871-023-02018-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2018"],"URL":"https:\/\/doi.org\/10.1186\/s12871-023-02018-y","relation":{},"ISSN":["1471-2253"],"issn-type":[{"value":"1471-2253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,16]]},"assertion":[{"value":"3 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Local Ethics Committee (Comitato Etico Regione Marche -CERM) and it conformed to the principles of Helsinki declaration. NCT02750163, trial registered on the 25\/04\/2016. In compliance with national applicable laws, informed consent was obtained from the subjects before inclusion; patients that were temporarily unable to consent for neurological impairment or sedation were included in the study with deferred subject consent and written informative for the next of kin at the time of enrollment (these patients did not belong to groups of vulnerable population).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}